Pictet Asset Management Holding SA Buys 251,578 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

Pictet Asset Management Holding SA lifted its stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 41.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 860,228 shares of the company’s stock after buying an additional 251,578 shares during the period. Pictet Asset Management Holding SA’s holdings in Kiniksa Pharmaceuticals International were worth $64,182,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Rubric Capital Management LP lifted its stake in Kiniksa Pharmaceuticals International by 12.7% during the 1st quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock valued at $180,562,000 after acquiring an additional 421,347 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Kiniksa Pharmaceuticals International by 18.8% in the first quarter. Dimensional Fund Advisors LP now owns 811,922 shares of the company’s stock valued at $39,086,000 after purchasing an additional 128,417 shares during the last quarter. Spruce Street Capital LP raised its holdings in shares of Kiniksa Pharmaceuticals International by 75.0% in the first quarter. Spruce Street Capital LP now owns 761,063 shares of the company’s stock valued at $36,645,000 after purchasing an additional 326,081 shares during the last quarter. Bank of America Corp DE raised its holdings in shares of Kiniksa Pharmaceuticals International by 220.9% in the first quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock valued at $35,436,000 after purchasing an additional 506,576 shares during the last quarter. Finally, Rice Hall James & Associates LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 2.0% during the first quarter. Rice Hall James & Associates LLC now owns 608,416 shares of the company’s stock valued at $29,295,000 after purchasing an additional 11,985 shares in the last quarter. Institutional investors own 53.95% of the company’s stock.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ:KNSA opened at $98.76 on Tuesday. Kiniksa Pharmaceuticals International, plc has a 1 year low of $37.02 and a 1 year high of $99.31. The company has a market capitalization of $7.71 billion, a PE ratio of 75.97 and a beta of 0.07. The business has a fifty day moving average price of $80.87 and a two-hundred day moving average price of $61.65.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its earnings results on Tuesday, October 27th. The company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. The company had revenue of $285.97 million for the quarter, compared to analysts’ expectations of $260.66 million. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. Sell-side analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on KNSA. Canaccord Genuity Group boosted their price target on shares of Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a report on Wednesday, July 29th. Citigroup upped their price objective on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Wedbush increased their price objective on shares of Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the company an “outperform” rating in a research note on Wednesday, October 28th. The Goldman Sachs Group lifted their target price on shares of Kiniksa Pharmaceuticals International from $90.00 to $101.00 and gave the stock a “buy” rating in a research report on Wednesday, October 28th. Finally, JPMorgan Chase & Co. boosted their target price on Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, Kiniksa Pharmaceuticals International currently has a consensus rating of “Moderate Buy” and a consensus target price of $100.57.

Insider Activity at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, CFO Mark Ragosa sold 36,783 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $92.16, for a total value of $3,389,921.28. Following the sale, the chief financial officer owned 20,854 shares of the company’s stock, valued at approximately $1,921,904.64. The trade was a 63.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Ross Moat sold 75,608 shares of the business’s stock in a transaction dated Friday, October 30th. The shares were sold at an average price of $93.13, for a total transaction of $7,041,373.04. Following the completion of the transaction, the chief operating officer owned 10,294 shares in the company, valued at approximately $958,680.22. The trade was a 88.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 831,022 shares of company stock valued at $77,475,599 in the last 90 days. 51.98% of the stock is currently owned by company insiders.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals International plc is a biopharmaceutical company focused on developing and commercializing treatments for patients with autoimmune and inflammatory diseases. The company was established in 2015 and has operations in the United States and internationally.

Kiniksa’s marketed medicine, Arcalyst (rilonacept), is approved in the United States to treat recurrent pericarditis and reduce the risk of recurrence in adults and certain pediatric patients. It is also approved for cryopyrin-associated periodic syndromes, a group of rare autoinflammatory conditions.

The company also develops investigational therapies for inflammatory and immune-mediated conditions, including treatments that target pathways involved in immune-cell activity.